亚洲依依成人综合网站,手机看片国内基地,日本性爱视频大全在线观看,秋水一色性福利导航,欧美A级V片在线观看,韩国论理片,欧美特色AAA大片,6一12泑女WWW,肥臀喷水上位

E-3810

    95%

E-3810

源葉(MedMol)
S80060
1058137-23-7
C26H25N3O4
443.49
CS-0782; Lucitanib; QC-4603; UNII-PP449XA4BH; E-3810 amine; 6-[[7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolyl]oxy]-N-methyl-naphthalene-1-carboxamide; 6-(7-((1-Aminocyclopropyl)methoxy)-6-metho
品牌 貨號 產品規格 價格(RMB) 庫存(上海) 北京 武漢 南京 購買數量
源葉(MedMol) S80060-5mg 95% ¥860.00元 10 - - -
源葉(MedMol) S80060-10mg 95% ¥1420.00元 9 - - -
源葉(MedMol) S80060-50mg 95% ¥3800.00元 2 - - -
產品介紹 參考文獻 質檢證書(COA) 摩爾濃度計算器 相關產品

產品介紹

Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
產品描述: Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.
靶點: VEGFR1:7 nM (IC50);VEGFR2:25 nM (IC50);VEGFR3:10 nM (IC50);FGFR1:17.5 nM (IC50);FGFR2:82.5 nM (IC50);VEGFR;FGFR
體內研究: Lucitanib (E-3810), at oral dosing of 20 mg/kg for 7 consecutive days, completely inhibits (P<0.01) the bFGF induced angiogenic response compare with the response in vehicle-treated mice. Lucitanib (E-3810) shows a broad spectrum of activity, being active in all the xenografts tested (HT29 colon carcinoma, A2780 ovarian carcinoma, A498, SN12K1, and RXF393 renal carcinomas) with dose-dependent inhibition of tumor growth. E-3810 significantly delays growth during treatment, but tumors resume their growth when treatment is suspended; in a few cases, tumor regression is observed. The activity of Lucitanib (E-3810) given at the doses of 15 mg/kg is tested on MDA-MB-231 breast cancer transplanted subcutaneously, at a late stage, when tumor masses reach 350 to 400 mg. This tumor xenograft is very sensitive to Lucitanib (E-3810), with complete tumor stabilization lasting throughout the 30-day treatment. As in other tumor models, tumors re-grow after withdrawal of Lucitanib (E-3810) at a rate similar to control tumors
參考文獻: 1. Bello E, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 2. Colzani M, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics. 2014 Jun;13(6):1495-509. 3. Bello E, et al. The tyrosine kinase inhibitor E-3810 combined with NSC 125973 inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther. 2013 Feb;12(2):131-40
溶解性: DMSO  :  ≥  20.83  mg/mL  (46.97  mM)
保存條件: -20℃
配置溶液濃度參考:
1mg 5mg 10mg
1 mM 2.255 ml 11.274 ml 22.548 ml
5 mM 0.451 ml 2.255 ml 4.51 ml
10 mM 0.225 ml 1.127 ml 2.255 ml
50 mM 0.045 ml 0.225 ml 0.451 ml
注意: 部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。

參考文獻

質檢證書(COA)

如何獲取質檢證書(COA)?
請輸入貨號和一個與之匹配的批號。
例如:
批號:JS298415 貨號:S20001-25g
在貨品標簽上如何找到貨號和批號?

摩爾濃度計算器

質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

=
×
×

相關產品